Latest Royalty Revenue News

Freedom Bidco has increased its unsolicited cash offer for Strata Investment Holdings to A$0.22 per share, presenting shareholders with a premium liquidity option ahead of Strata’s imminent ASX delisting. The offer includes a cash alternative and a share swap, while Freedom Bidco accuses Strata’s board of obstructive tactics and governance failings.

Wide Open Agriculture has agreed with Curtin University to replace its tiered royalty structure with a single 3.5% flat royalty on net sales, streamlining financial planning and enhancing commercial scalability for its lupin protein technology.

BrainChip Holdings has signed a global IP license agreement with ASICLAND, enabling integration of its Akida neuromorphic AI technology into custom SoC designs with a royalty-based revenue model.

Emmerson Resources is set to be acquired by Pan African Resources for approximately A$311 million, offering shareholders a 36% premium. The company also advances a government-backed feasibility study for a shared processing facility and begins royalty revenue inflows.

Anagenics Limited delivered a third quarter operational performance aligned with budget following its restructuring, with cash outflows narrowing and its Bouf Haircare brand generating robust royalty revenue.

Red Hill Minerals has reported a robust half-year performance for FY26, driven by strong royalty revenue from the Onslow Iron Ore Project and ongoing exploration investments. The company declared an interim fully franked dividend of 11.6 cents per share.

Deterra Royalties reported a robust December quarter with record iron ore royalty revenue from Mining Area C and significant progress on the Thacker Pass lithium project, backed by a US$435 million DOE loan draw.

Cauldron Energy Limited has unveiled significant uranium discoveries at its Yanrey Project, bolstering its resource base as uranium prices surge on strong global demand and strategic investments.

Red Hill Minerals reported a solid $7.8 million royalty from its Onslow Iron Project and unveiled promising exploration results across its Broken Hill and Anabama projects, reinforcing its growth trajectory.

Anagenics Limited reports a significant turnaround with profitable trading in the second quarter of FY26, driven by strong brand performance and a successful capital raise. The company is poised for growth with expanding product lines and international ambitions.

Neuren Pharmaceuticals has affirmed the material impact of Acadia’s projection that DAYBUE global net sales could reach approximately US$700 million by 2028, underpinning its royalty revenue outlook.

Neuren Pharmaceuticals’ partner Acadia secures FDA approval for DAYBUE STIX, a new powder formulation of trofinetide offering greater flexibility for Rett syndrome patients. This milestone expands treatment options and sets the stage for increased royalty revenue in 2026.